Genitourinary Cancer

MD IQ

Feature

Company discontinues phase 3 ADAPT for mRCC

A second interim analysis of the trial comparing Rocapuldencel-T in combination with sunitinib to sunitinib monotherapy led Argos Therapeutics to...

Pages